<DOC>
	<DOCNO>NCT01997190</DOCNO>
	<brief_summary>This phase I study intrapleural AdV-tk therapy patient malignant pleural effusion ( MPE ) . The primary objective test safety intrapleural AdV-tk therapy . Secondary objective evaluate clinical efficacy biologic activity</brief_summary>
	<brief_title>Intrapleural AdV-tk Therapy Patients With Malignant Pleural Effusion</brief_title>
	<detailed_description>The goal open-label , dose escalation clinical trial investigate administration AdV-tk patient MPE follow valacyclovir chemotherapy safe , effectively deliver without disturb standard therapy , anti-tumor activity patient solid tumor . The first second dose level complete , study currently expand enroll patient dose level 2 Celecoxib . Patients receive one injection AdV-tk pleural catheter day 0 . The prodrug , valacyclovir , administer orally fix dose 14 day AdV-tk injection . Celecoxib administer start 3 day AdV-tk continue 2 day AdV-tk administration . Chemotherapy may begin time completion valacyclovir . Choice chemotherapy depend treat oncologist .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Patients must MPE ( define positive pleural fluid cytology ) . Eligible patient include NSCLC , small cell lung cancer , malignant mesothelioma ( MM ) , breast cancer ovarian cancer . Diagnosis must make prior AdVtk injection . For patient MM , histologic proof need , positive pleural fluid cytology require . Patients must indication placement pleural catheter Patients must 18 year age old Performance status must ECOG 01 Acute toxic effect prior radiotherapy , chemotherapy , prior surgical procedure must resolve NCI CTCAE v 4.0 grade ≤ 1 Baseline pulmonary function test must FEV1 ≥1 liter 40 % predict value ( may postdrainage and/or bronchodilator ) Bilirubin ≤ 1.5 x upper limit normal ( ULN ) ALT , AST alkaline phosphatase ≤ 2 x ULN Serum creatinine &lt; 2 mg/dl calculate creatinine clearance &gt; 30 ml/min Hemoglobin ≥ 9 g/dL , ANC &gt; 1000/mm3 platelet &gt; 100,000/mm3 Serum albumin level ≥ 2.5 g/dL Patients must give study specific inform consent prior enrollment Patients may systemic corticosteroid ( &gt; 10 mg prednisone per day ) systemic immunosuppressive drug Patient know HIV+ Patient pregnant breastfeeding . Female patient childbearing age must negative serum urine pregnancy test within 1 week begin therapy . Patient may clinically significant pericardial effusion Patient may serious comorbid illness compromise organ function Patient may liver disease include known cirrhosis , active hepatitis chronic active hepatitis B No prior allergic reaction hypersensitivity sulfonamide , celecoxib , aspirin NSAIDs No concurrent use NSAID aspirin exceed 100mg/day celecoxib administration . No washout period require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Tumor vaccine</keyword>
</DOC>